Sat, Sep 20, 2014, 11:17 AM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • thirdmeinvestor thirdmeinvestor Jan 24, 2012 7:53 PM Flag

    How is “1” greater than “4”?

    If you assume that the yearly treatment cost for Kalydeco is 150k (not 250k Credit Swiss assumes), VRTX earnings from Kalydeco sales in 2013 would be about $1/shr. But the earnings from Incivek will be about $4/shr. I want to show that the quality of the former earnings is better than the latter.

    Initially, the sales force will target a group of 2000 G551D CF gene carriers in the US and EU. This figure corresponds to 3% (not 1.6%) of all CFers in the two regions. The annual revenue and income from the sales are not only repeatable year after year (because there is no competitor) for many years but will also increase many fold in the subsequent years because the sales will expand to treat R117H and other gating mutations. In three years Kalydeco will have a great chance of treating 7% (=3+3+1) of all CFers. An additional 1% will be added to this sum if 2-5 years olds can be treated. This 8% of all CFer in the regions corresponds to about 5000 people. This means a 150% growth of sales and about a 200% growth of earnings from the baseline of the Year 2013’s. Since this growth would occur over two years (three years from now), the annual growth rate would be 141%.

    The demand expansion for Kalydeco does not stop there. The trial for CF gene F508del will be a success, even if it is a modest improvement over the earlier Phase 2, the % of all CFers who will benefit from the VX-809/Kalydeco combination will increase by 48k people(69%x70k) from the current target of 2k. This is a 2300% increase.

    Now assume that the PEG ratio is 1. What do you get for the value of Kalydeco alone?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
103.75+6.40(+6.57%)Sep 19 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
AutoZone, Inc.
NYSEFri, Sep 19, 2014 4:02 PM EDT
Dresser-Rand Group Inc.
NYSEFri, Sep 19, 2014 4:04 PM EDT